Endogenous retroviruses (ERVs) are emerging as promising therapeutic targets in cancer.
As remnants of ancient retroviral infections, ERV-derived regulatory elements coordinate …

Our defenses against infection rely on the ability of the immune system to distinguish
invading pathogens from self. This task is exceptionally challenging, if not seemingly …

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …

Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of
cancer patients. Recent evidence suggests that epigenetic therapies synergize with …

Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

Hypomethylating agents (HMAs) are frontline therapies for Myelodysplastic Neoplasms
(MDS) and Acute Myeloid Leukemia (AML). However, acquired resistance and treatment …

Human Endogenous Retroviruses (HERVs) are accounting for 8% of the human genome.
These sequences are remnants from ancient germline infections by exogenous retroviruses …

Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies
characterized by ineffective hematopoiesis, with increased incidence in older individuals …

Human endogenous retroviruses (HERVs) represent 8% of the human genome. The
expression of HERVs and their immune impact have not been extensively studied in Acute …